Shares of Indivior PLC (NASDAQ:INDV – Get Free Report) saw unusually-high trading volume on Friday . Approximately 419,314 shares changed hands during mid-day trading, an increase of 6% from the previous session’s volume of 396,994 shares.The stock last traded at $7.58 and had previously closed at $7.98.
Wall Street Analysts Forecast Growth
INDV has been the subject of a number of research analyst reports. Craig Hallum lowered their price target on Indivior from $20.00 to $16.00 and set a “buy” rating for the company in a report on Friday. Piper Sandler reiterated an “overweight” rating and issued a $15.00 target price (down previously from $22.00) on shares of Indivior in a research report on Friday.
Check Out Our Latest Stock Report on Indivior
Indivior Stock Performance
Indivior (NASDAQ:INDV – Get Free Report) last announced its quarterly earnings results on Thursday, July 25th. The company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.40 by $0.04. Indivior had a negative net margin of 12.29% and a negative return on equity of 654.82%. The company had revenue of $299.00 million during the quarter, compared to the consensus estimate of $285.90 million. As a group, equities analysts predict that Indivior PLC will post 1.7 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the company. M&G Plc bought a new position in Indivior during the 1st quarter worth approximately $2,518,000. Janus Henderson Group PLC raised its position in shares of Indivior by 14.2% in the 1st quarter. Janus Henderson Group PLC now owns 440,121 shares of the company’s stock worth $9,424,000 after acquiring an additional 54,750 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Indivior by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 5,899,190 shares of the company’s stock worth $90,081,000 after acquiring an additional 52,836 shares in the last quarter. Quadrature Capital Ltd bought a new position in shares of Indivior during the 1st quarter worth approximately $1,523,000. Finally, Susquehanna International Group Ltd. acquired a new position in shares of Indivior during the 2nd quarter valued at $3,224,000. Institutional investors and hedge funds own 60.33% of the company’s stock.
About Indivior
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Featured Articles
- Five stocks we like better than Indivior
- 3 REITs to Buy and Hold for the Long Term
- 3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
- What Investors Need to Know to Beat the Market
- Autodesk Named a “Top Pick” by Morgan Stanley—Is It Time to Buy?
- The Basics of Support and Resistance
- 4 Quirky ETFs With Big Potential for Impressive Gains
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.